Drug Trial Radar · NCT02611973
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Last checked: Nov 19, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,250
Planned (sponsor's estimate)
Start
Mar 10, 2016
Primary completion
Nov 2019
Study completion Nov 2022
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients. Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.
Conditions
- MPN
- Essential Thrombocythemia
Interventions
Aspirin therapy interruptionOther
Stop the treatment by aspirin 100mg/d in the experimental arm.
Usual treatment by aspirin 100 mg/d in the active comparator armOther
HU+ aspirin maintenance
No interruption of aspirin in the Observational armOther
patient with Contre indication to aspirin or required antithrombotic therapy
Hydroxyurea treatment (HU)Drug
HU maintenance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence of death from vascular origin and other thrombotic and hemorrhagic events (combined endpoint)Time frame: at 2-years follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henri Mondor Hospital
Créteil, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.